14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.
Genkyotex
First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.
Genkyotex
Design of Benzyl-triazolopyrimidine-Based NADPH Oxidase Inhibitors Leads to the Discovery of a Potent Dual Covalent NOX2/MAOB Inhibitor.
Sapienza University of Rome
Targeting NOX2 with Bivalent Small-Molecule p47phox-p22phox Inhibitors.
University of Copenhagen
Discovery of a NADPH oxidase inhibitor, (E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl)amino)benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease.
Korea University
Bridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitors.
University of Pittsburgh
The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health.
Msd The Francis Crick Institute
BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION COMPRISING SAME, AND APPLICATION THEREOF
Hangzhou Apeloa Medicine Research Institute Co.